We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Smartphone-Powered Microfluidic ‘Lab on a Strip’ Dengue Test More Powerful Than LFT Testing

By LabMedica International staff writers
Posted on 11 Apr 2022

Dengue fever affects an estimated 400 million people each year. More...

While most cases are mild, dengue infections can lead to significant complications and can be fatal. Dengue can be most severe in children and is a serious health challenge facing half the global population. Now, new ‘lab on a strip’ technology has shown the capability of smartphone-powered tests for dengue fever.

Biomedical technology researchers from the University of Reading (London, UK) have developed the new diagnostic test for research that uses ‘lab on a strip’ technology, which performs 10 or more tests a very small amount of liquid sample (such as blood, urine or saliva). The researchers used a new diagnostic kit called Cygnus to detect dengue fever with significantly improved rates over lateral flow testing kits.

The team trialled the tests alongside already established alternatives and found the new tests showed 82% clinical sensitivity, beating lateral flow testing (74% sensitivity) and matching hospital-based lab diagnostics (83% sensitivity). At the same time, these devices make 10 measurements allowing us to identify which of the four different dengue virus types caused the infection.

“The paper shows exciting potential for the use of the microfluidic ‘lab on a strip’ tests that can be used in conjunction with a smartphone and are more powerful than LFT testing in this case,” said Dr. Sarah Needs, Postdoctoral Research Associate in Microfluidic Antimicrobial Resistance Testing from the University of Reading. “As well as being cheap to produce, the lab on a strip technology allows users to test many different targets at once in one single sample, so it could be useful to detect multiple diseases not just one.”

“While some people might only recently learned of the trade-offs between home vs. lab testing following COVID-19, in many parts of the world rapid lateral flow tests are used for a range of illnesses including dengue,” added Dr. Alexander Edwards, Associate Professor in Biomedical Technology at the University of Reading co-created the lab on a strip technology. “With the Cygnus concept, we are tackling the biggest hurdle for home testing. How do you make something portable that can be cheaply mass produced while still matching laboratory test performance? By designing the microfluidic lab on a strip using mass-production melt-extrusion it is possible to scale up production and produce hundreds of thousands of tests. By recording results with smartphones, which are becoming ubiquitous, we have designed something that could be revolutionary for healthcare.”

Related Links:
University of Reading 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Galleri is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without recommended screening (Photo courtesy of GRAIL)

Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval

GRAIL’s Galleri multi-cancer early detection (MCED) test was reviewed by the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration’s (FDA) Medical Devices Advisory Committee.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.